TopFunds

Eli Lilly And Co

NYSE: LLY

Stock price

1257.03 USD

(+0%) TODAY

medicineDrug Manufacturers - General
Financials

all figures in US$ Millions except per share data

Sections:

Periods:

View:

Format:

Actual
10 year cagr
Help
Where available up to 10y CAGR shown for absolute numbers 10y Average marked A shown for relative numbers such as margins
Fiscal
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Average (A)
Fiscal period end dates
Expand all rows
01Earnings per share
Help
Earnings per share = Net Income / Number of Shares Outstanding
2.2
2.5
(0.2)
3.1
8.7
6.5
5.9
6.6
5.8
11.7
23
26.5%
02Free cash flow per share
1.2
3.4
3.3
2.4
3.6
4.7
5.6
4.8
(3.5)
4.2
10
23.5%
03Dividends per share
2
2
2.1
2.3
2.6
3
3.4
3.9
4.5
5.2
6
11.6%
04Dividends payout, %
88.3%
78.9%
(10.7)%
71.5%
29%
43.4%
55.3%
56.6%
77.7%
44.2%
26.1%
(11.5)%
PROFIT AND LOSS STATEMENT
05Revenue
19,959
21,222
19,974
21,493
22,320
24,540
28,318
28,541
34,124
45,043
65,179
12.6%
06% Change
-
-
-
-
-
-
-
-
-
-
-
12.6%
07Cost of revenue
(5,037)
(5,710)
(4,448)
(4,682)
(4,721)
(5,483)
(7,313)
(6,630)
(7,082)
(8,418)
(11,052)
8.2%
08Gross profit
14,922
15,512
15,526
16,812
17,598
19,057
21,006
21,912
27,042
36,625
54,127
13.8%
09% Margin
74.8%
73.1%
77.7%
78.2%
78.9%
77.7%
74.2%
76.8%
79.3%
81.3%
83%
77.7% A
10Operating expenses
(11,329)
(11,641)
(11,276)
(10,786)
(11,599)
(11,846)
(13,073)
(13,258)
(16,255)
(19,585)
(24,431)
8%
11% of Revenue
(56.8)%
(54.9)%
(56.5)%
(50.2)%
(52)%
(48.3)%
(46.2)%
(46.5)%
(47.6)%
(43.5)%
(37.5)%
(49.1)% A
12Operating Income
3,592
3,871
4,250
6,026
5,999
7,211
7,933
8,653
10,787
17,040
29,696
23.5%
13Income tax expense
(381.6)
(636.4)
(2,391)
(529.5)
(628)
(1,036)
(573.8)
(561.6)
(1,314)
(2,090)
(5,091)
29.6%
14Net Income
2,408
2,738
(204.1)
3,232
8,318
6,194
5,582
6,245
5,240
10,590
20,640
24%
15% Margin
12.1%
12.9%
(1)%
15%
37.3%
25.2%
19.7%
21.9%
15.4%
23.5%
31.7%
19.4% A
16Shares Outstanding
1,105
1,101
1,052
1,034
957.5
956.6
953.7
950.2
903.3
904.1
898
(2.1)%
17EPS Basic
2.2
2.5
(0.2)
3.1
8.7
6.5
5.9
6.6
5.8
11.8
23.1
26.6%
18EPS Diluted
2.2
2.5
(0.2)
3.1
8.7
6.5
5.9
6.6
5.8
11.7
23
26.5%
19EBITDA
4,379
5,056
4,097
5,532
6,899
8,913
8,043
8,661
8,568
18,807
31,693
21.9%
% Margin
21.9%
23.8%
20.5%
25.7%
30.9%
36.3%
28.4%
30.3%
25.1%
41.8%
48.6%
30.3% A
20Net Interest Income (expense)
(74.2)
(76.5)
(58.6)
(83.2)
(320.2)
(326.6)
(314.4)
(268.8)
(312.3)
(605.4)
(642)
24.1%
21Net Debt / EBITDA
1
1.1
1.7
0.5
2
1.5
1.6
1.6
2.6
1.6
1.1
1.5 A
BALANCE SHEET
ASSETS
Current Assets
22Cash & equivalents
3,666
4,582
6,536
7,321
2,338
3,657
3,819
2,067
2,819
3,268
7,163
6.9%
23Short-term investments
785.4
1,457
1,498
88.2
101
24.2
90.1
144.8
109.1
154.8
105
(18.2)%
24Accounts receivable
4,072
4,766
5,262
5,777
5,542
6,929
8,127
8,559
11,336
13,275
20,155
17.3%
25Other current assets
604.4
734.6
1,448
4,266
2,539
2,872
2,531
2,954
5,690
8,452
14,462
37.4%
26Inventory
3,446
3,562
4,458
3,098
3,191
3,980
3,886
4,310
5,773
7,589
13,744
14.8%
27Total Current Assets
12,574
15,101
19,202
20,550
13,710
17,462
18,452
18,035
25,727
32,740
55,629
16%
Non-Current Assets
28Net property, plant & equipment
8,054
8,253
8,827
7,996
8,405
8,682
8,985
10,144
12,914
17,102
24,675
11.9%
29Long-term investments
3,647
5,208
5,679
2,018
1,962
2,967
3,213
2,902
3,052
3,216
2,802
(2.6)%
30Other non-current assets
11,295
10,244
11,274
13,345
15,209
17,522
18,156
18,410
22,314
25,657
29,370
10%
31Total Non-Current Assets
22,995
23,705
25,779
23,359
25,577
29,171
30,354
31,455
38,279
45,975
56,847
9.5%
Total Assets
35,569
38,806
44,981
43,908
39,286
46,633
48,806
49,490
64,006
78,715
112,476
12.2%
LIABILITIES
Current Liabilities
32Accounts payable
1,338
1,349
1,411
1,207
1,405
1,607
1,671
1,931
2,599
3,229
5,379
14.9%
33Short-term debt
6.1
1,937
3,707
1,102
1,499
8.7
1,538
1,501
6,905
5,117
1,635
74.9%
34Other current liabilities
6,885
7,700
9,419
9,579
8,871
10,866
11,844
13,707
17,790
20,031
28,214
15.2%
35Total Current Liabilities
8,230
10,987
14,536
11,888
11,775
12,482
15,053
17,138
27,293
28,377
35,228
15.7%
Non-Current Liabilities
36Long-term debt
7,972
8,368
9,932
9,196
14,305
16,587
15,346
14,738
18,321
28,527
40,868
17.8%
37Other non-current liabilities
4,777
5,371
8,845
11,915
10,507
11,740
9,252
6,839
7,529
7,540
9,845
7.5%
38Total Non-Current Liabilities
12,749
13,739
18,777
21,111
24,812
28,326
24,599
21,576
25,849
36,067
50,713
14.8%
39Total Liabilities
20,979
24,725
33,313
32,999
36,587
40,808
39,651
38,714
53,143
64,443
85,941
15.1%
SHAREHOLDERS` EQUITY
40Common stock
691.3
688.5
687.9
661
598.8
598.2
596.3
594.1
593.6
592.4
590
(1.6)%
41Retained earnings / (deficit)
16,012
16,046
13,894
11,396
4,920
7,830
8,959
10,043
10,312
13,545
24,470
4.3%
42Accumulated other comprehensive income / (loss)
(4,581)
(8,287)
(8,732)
(8,742)
(6,524)
(9,510)
(4,343)
(3,845)
(4,327)
(4,322)
(2,880)
(4.5)%
43Noncontrolling interests
19
72.8
75.7
1,080
92.2
183.6
175.6
125.6
91.8
79.5
-
-
44Total shareholders' equity
14,590
14,081
11,668
10,909
2,699
5,825
9,155
10,775
10,864
14,272
26,535
6.2%
45Total Liabilities and shareholders' Equity
35,569
38,806
44,981
43,908
39,286
46,633
48,806
49,490
64,006
78,715
112,476
12.2%
46Total Debt
7,979
10,305
13,647
10,299
15,804
16,595
16,885
16,239
25,225
33,644
42,503
18.2%
47Net Debt
4,312
5,723
7,111
2,978
13,466
12,938
13,066
14,172
22,407
30,376
35,340
23.4%
CASH FLOW STATEMENT
CASH FLOWS FROM OPERATING ACTIVITIES
48Net income (loss)
2,408
2,738
(204.1)
3,232
8,318
6,194
5,582
6,245
5,240
10,590
20,640
24%
49Depreciation & amortization
1,428
1,497
1,567
1,609
1,233
1,324
1,548
1,523
1,527
1,767
1,997
3.4%
50Share-based compensation expense
217.8
255.3
281.3
279.5
312.4
308.1
342.8
371.1
628.5
645.6
626
11.1%
51Changes in working capital and other assets
(1,089)
361.5
3,971
404
(5,027)
(1,326)
(106.2)
(552.7)
(3,156)
(4,184)
(6,450)
19.5%
52Net cash flows from operating activities
2,965
4,851
5,616
5,525
4,837
6,500
7,366
7,586
4,240
8,818
16,813
19%
CASH FLOWS FROM INVESTING ACTIVITIES
53Purchases of property, plant and equipment
(1,626)
(1,092)
(2,164)
(1,211)
(1,354)
(2,029)
(1,310)
(1,854)
(3,448)
(8,404)
(7,841)
17%
54Purchases of investments / marketable securities
(4,069)
(5,673)
(8,001)
(950.1)
(290.2)
(370.1)
(1,013)
(707.6)
(829)
(775.8)
(645)
(16.8)%
55Proceeds from maturities of marketable securities
5,230
3,728
7,439
6,062
746.4
886.8
847.4
463.6
700.3
522.5
964
(15.6)%
56Other investing activities
491.5
(101.7)
(1,057)
(1,995)
(7,186)
(746.5)
(1,392)
(1,665)
(3,576)
(644.6)
(3,450)
-
57Net cash flows from investing activities
26.8
(3,139)
(3,784)
1,906
(8,083)
(2,259)
(2,868)
(3,763)
(7,153)
(9,302)
(10,972)
-
CASH FLOWS FROM FINANCING ACTIVITIES
58Issuance (repurchases) of common stock, net
(749.5)
(600.1)
(299.8)
(2,491)
(4,400)
(500)
(1,250)
(1,500)
(750)
(2,500)
(4,108)
18.6%
59Dividends paid, net
(2,127)
(2,159)
(2,192)
(2,312)
(2,410)
(2,687)
(3,087)
(3,536)
(4,069)
(4,680)
(5,384)
9.7%
60Debt issuance (repayments), net
(181.6)
2,500
2,999
(729.3)
4,685
291.6
501.4
(62)
8,650
8,901
8,051
-
61Other financing activities
139.2
(300.8)
(364.4)
(372.8)
(200.1)
(241.6)
(295.9)
(308.9)
(335)
(490.6)
(772)
-
62Net cash flows from financing activities
(2,919)
(559.8)
142.6
(5,905)
(2,325)
(3,137)
(4,131)
(5,407)
3,496
1,230
(2,213)
(2.7)%
63Increase (decrease) in cash and cash equivalents
(205.2)
915.7
1,954
1,462
(5,661)
1,320
161.4
(1,752)
751.6
449.8
4,000
-
64Cash and equivalents, ending balance
3,666
4,582
6,536
7,998
2,338
3,657
3,819
2,067
2,819
3,268
7,268
7.1%
65Free Cash Flow to the Firm (FCFF)
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities - Capital Expenditures
1,338
3,759
3,452
4,314
3,483
4,471
6,056
5,731
792.5
414.3
8,972
21%

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
2025202420232022202120202019201820172016

Eli Lilly And Co (LLY) financial statements and performance

Explore Eli Lilly And Co (LLY) annual and quarterly financial statements, including revenue, operating income, net income, cash flow, assets, liabilities, and per-share metrics.

Compare reporting periods and financial trends to evaluate profitability, balance-sheet strength, cash generation, and long-term business performance.